ALK-Abello A/S 2012 AR2
The report highlights ALK's financial and operational performance for the fiscal year 2012, focusing on the globalization of its allergy immunotherapy products. Despite challenging European markets, the company advanced its clinical pipeline, with over 8,000 patients participating in trials, and progressed its partnerships in North America and Japan. ALK initiated its 'Focus 2016' strategy to simplify its product portfolio, consolidate production, and streamline business structures. In sustainability, the company reduced its CO2 emissions by 13% compared to 2008 through increased use of renewable energy and maintained its ISO 14001 and OHSAS 18001 certifications in Denmark.
Company: ALK-Abello A/S
Sector: Manufacturing
Country: Denmark
Year: 2012
Type: AR2
Pages: 72
Back to company
ALK-Abello A/S
Annual Report
The report highlights ALK's financial and operational performance for the fiscal year 2012, focusing on the globalization of its allergy immunotherapy products. Despite challenging European markets, the company advanced its clinical pipeline, with over 8,000 patients participating in trials, and progressed its partnerships in North America and Japan. ALK initiated its 'Focus 2016' strategy to simplify its product portfolio, consolidate production, and streamline business structures. In sustainability, the company reduced its CO2 emissions by 13% compared to 2008 through increased use of renewable energy and maintained its ISO 14001 and OHSAS 18001 certifications in Denmark.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Jan 1, 2012 - Dec 31, 2012
Fiscal Year
2012
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees